Forma Therapeutics Holdings, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Frank D. Lee
- Full Time Employees
- 189
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 500 Arsenal Street Watertown MA United States of America 02472
- IPO Date
- Jun 19, 2020
- CIK
- 0001538927
- Website
- formatherapeutics.com
- Similar Companies
- Business
- Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes novel therapeutics for rare hematologic diseases and cancers, including sickle cell disease, thalassemia, myelodysplastic syndromes, metastatic castration-resistant prostate cancer, acute myeloid leukemia, and glioma. The company's lead product candidate, etavopivat (FT-4202), is an oral, once-daily pyruvate kinase-R activator in Phase II/III trials for sickle cell disease and Phase II trials for transfusion-dependent thalassemia and myelodysplastic syndromes; FT-7051, a CBP/p300 inhibitor, advances in Phase I trials for metastatic castration-resistant prostate cancer; olutasidenib, a selective IDH1 inhibitor, progresses in Phase II for relapsed/refractory IDH1-mutant acute myeloid leukemia and Phase I for glioma; FT-8225, a liver-targeted fatty acid synthase inhibitor, targets de novo lipogenesis disorders; and early-stage programs include FT-3171, a USP1 inhibitor for DNA damage repair in tumors. Founded in 2007 and headquartered in Watertown, Massachusetts, the company operates primarily in the United States and serves patients with hematologic and oncologic conditions through its research and clinical pipeline. As of October 2022, Forma Therapeutics Holdings, Inc. operates as a wholly-owned subsidiary of Novo Nordisk A/S following a $1.1 billion acquisition, with no major subsequent acquisitions, funding rounds, or product launches reported in the last two years.
Novo Nordisk announces the completion of the Forma Therapeutics acquisition
FORMA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forma Therapeutics, Holdings Inc. - FMTX
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GMTX, FMTX, TRQ, SGFY
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IEA, CYBE, FMTX, TRQ
Forma Therapeutics shares jump 50%; here is why
FORMA THERAPEUTICS INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forma Therapeutics, Holdings Inc. - FMTX
SHAREHOLDER ALERT: Weiss Law Investigates Forma Therapeutics Holdings, Inc.
Why Forma Therapeutics Holdings Stock Is On Fire Today
Novo Nordisk Jumps Into Sickle Cell Fray With $1.1 Billion Forma Therapeutics Buyout
Why Novo Nordisk (NVO) Is Buying Forma Therapeutics (FMTX) For $1.1 Billion
Novo Nordisk to acquire Forma Therapeutics in $1.1. billion deal
Forma Therapeutics to be acquired by Novo Nordisk in a cash deal valued at $1.1 billion
Forma Therapeutics: Rare Disease Play
Forma Therapeutics Holdings Inc. (FMTX) CEO Frank Lee on Q2 2022 Results - Earnings Call Transcript
Forma Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
Forma Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 5, 2022
Can Forma Therapeutics Holdings, Inc. (FMTX) Climb 536% to Reach the Level Wall Street Analysts Expect?
Bears are Losing Control Over Forma Therapeutics Holdings, Inc. (FMTX), Here's Why It's a 'Buy' Now
Forma Therapeutics to Present at the Jefferies Healthcare Conference
Forma Therapeutics Holdings Inc. (FMTX) CEO Frank Lee on Q1 2022 Results - Earnings Call Transcript